Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists

Bioorganic & Medicinal Chemistry
Xiaowu DongYongzhou Hu

Abstract

The pharmacophore model (Hypo1) with a well prediction capacity for CysLT(1) antagonists was developed using Catalyst/HypoGen program. Virtual screening against an in-house database consisted of carboxylated chalcones using Hypo1 was performed. Retrieved hits 26a, 26b, 27a, and 27b were synthesized and biological evaluated, the results of which demonstrated that these compounds showed moderate to good CysLT(1) antagonistic activities. This study indicated that the generated model (Hypo1) is a reliable and useful tool in lead optimization for novel CysLT(1) antagonists.

References

Aug 26, 1998·Drugs·A Markham, D Faulds
Oct 2, 2003·Prostaglandins & Other Lipid Mediators·Valérie CapraG Enrico Rovati
Sep 24, 2009·Allergy and Asthma Proceedings·Philip Lieberman
Feb 26, 2010·Expert Opinion on Therapeutic Patents·Carlo Pergola, Oliver Werz

❮ Previous
Next ❯

Citations

Oct 1, 2014·Journal of Biomolecular Structure & Dynamics·Tanos Celmar Costa França

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.